findmyKOL
Clinical trialNCT01075399CompletedPhase 2Interventional

Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors

SponsorSiemens Molecular ImagingEnrollment50Cervical CancerHead and Neck CancerLiver CancerLung CancerRectal Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This pilot phase II study is designed as a test and retest study to investigate \[F 18\]HX4 as a reliable non-invasive PET imaging marker for detection of tumor hypoxia regions and to establish a threshold for \[F 18\]HX4 uptake in the tumor. The study will evaluate the relationship between hypoxia biomarkers (HIF1α and CA-IX) by immunohistochemistry (IHC) and tumor uptake of \[F 18\]HX4 by PET imaging.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Alan Waxman, MD

    Cedars-Sinai Medical Center, Los Angeles, CA

    Principal Investigator
    clinicaltrials.gov ↗
  • Dae-Hyuk Moon, MD

    University of Ulsan College of Medicine, Asan Medical Center, Songpa-gu, Seoul, Korea

    Principal Investigator
    clinicaltrials.gov ↗
  • Jacqueline Brunetti, MD

    Holy Name Hospital

    Principal Investigator
    clinicaltrials.gov ↗
  • John M Buatti, MD

    University of Iowa Hospitals and Clinics, Carver College of Medicine, and Holden Comprehensive Cancer Center,Iowa City, Iowa

    Principal InvestigatorKOL profile →
    clinicaltrials.gov ↗
  • Kyung-Han Lee, MD

    Sungkyunkwan University School of Medicine, Samsung Medical Center, Gangnam-gu, Seoul, Korea

    Principal Investigator
    clinicaltrials.gov ↗
  • Nasrin Ghesani, MD

    University of Medicine and Dentistry of New Jersey, NJMS-UH/UMDNJ Cancer Center, and University Heights Advanced Imaging Center, Newark, NJ

    Principal Investigator
    clinicaltrials.gov ↗
  • Orhan Nalcioglu, PhD

    University of California Irvine Medical Center, Orange, CA

    Principal Investigator
    clinicaltrials.gov ↗
  • Rathan Subamaniam, MD

    Boston Medical Center, Boston, MA

    Principal Investigator
    clinicaltrials.gov ↗
  • Scott Dessain, MD, PhD

    Lankenau Institute for Medical Research, Wynnewood, PA and Bryn Mawr Hospital Outpatient Imaging Center, Bryn Mawr, PA

    Principal Investigator
    clinicaltrials.gov ↗
  • Shyam Srinivas, MD, PhD

    Cleveland Clinic, Cleveland, OH

    Principal Investigator
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

[F 18]HX4
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
28 Feb 2010
Primary completion
31 May 2011
Completion
29 Feb 2012
Last update posted
30 Aug 2013
Registered enrollment
50
Registry id
NCT01075399
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.